Evenity (Romosozumab) Adolescent (12-17) Safety

Why Romosozumab Has No Adolescent Indication

Romosozumab was developed and tested exclusively in postmenopausal women and older men with osteoporosis. The FDA approved it in April 2019 for postmenopausal women at high fracture risk, based primarily on the FRAME and ARCH trials. Neither study enrolled anyone younger than 55.

The ARCH trial (N=4,093) compared romosozumab to alendronate in postmenopausal women and demonstrated a 48% relative risk reduction in new vertebral fractures at 24 months [1]. The median participant age was 74 years. FRAME (N=7,180) compared romosozumab to placebo and showed a 73% reduction in new vertebral fractures at 12 months [2]. Both trials excluded premenopausal women entirely.

Amgen's prescribing label states that "safety and effectiveness in pediatric patients have not been established" [3]. This is not unusual for osteoporosis drugs. Bisphosphonates, denosumab, and teriparatide all carry similar pediatric exclusions in their primary labeling. The difference with romosozumab is the cardiovascular boxed warning, which raises the threshold for off-label experimentation considerably.

The Cardiovascular Boxed Warning and What It Means for Younger Patients

The FDA's boxed warning on romosozumab states that the drug "may increase the risk of myocardial infarction, stroke, and cardiovascular death" and should not be used in patients who have had a myocardial infarction or stroke within the preceding year [3]. This warning emerged from the ARCH trial, where the romosozumab-to-alendronate sequence showed a higher rate of adjudicated major adverse cardiovascular events (MACE) compared to alendronate alone: 2.5% vs. 1.9% over the first 12-month treatment period [1].

Adolescents generally have low baseline cardiovascular risk. That observation might seem reassuring, but it is not sufficient to dismiss the concern. The mechanism by which romosozumab might affect cardiovascular tissue is not fully understood. Sclerostin is expressed in vascular smooth muscle cells and aortic valve tissue, and some researchers hypothesize that inhibiting sclerostin could promote vascular calcification [4]. Whether this mechanism operates differently in adolescent vasculature, where atherosclerotic burden is minimal, remains unknown.

Dr. Felicia Cosman, professor of medicine at Columbia University and an investigator on the FRAME trial, has stated: "We simply do not have the data to extrapolate the cardiovascular safety profile of romosozumab to populations that were never studied, including younger patients and those without postmenopausal osteoporosis" [5]. This statement underscores the fundamental gap: absence of harm in a population that was never exposed is not evidence of safety.

Sclerostin Inhibition and the Growing Skeleton

Sclerostin, the protein target of romosozumab, is produced primarily by osteocytes and functions as an inhibitor of the Wnt signaling pathway. By blocking sclerostin, romosozumab activates osteoblast-mediated bone formation while simultaneously reducing bone resorption. In adults with established osteoporosis, this dual mechanism produces rapid gains in bone mineral density (BMD). The FRAME trial showed lumbar spine BMD increases of 13.3% at 12 months with romosozumab versus 0.0% with placebo [2].

The adolescent skeleton is a different biological environment. Growth plates (physes) remain open. Endochondral ossification is actively converting cartilage to bone. Periosteal expansion and cortical modeling are ongoing. Sclerostin's role in these processes is not well mapped.

Animal data offer some clues but raise questions. In sclerostin-knockout mice, bones are denser but also more brittle in some models, with altered cortical geometry [6]. A 2014 study in growing rats treated with sclerostin antibody showed increased trabecular and cortical bone mass, but the investigators noted changes in growth plate morphology that warrant caution before clinical translation to human adolescents [7].

Three specific concerns emerge for the 12-17 age group:

1. Growth plate effects. If sclerostin inhibition alters chondrocyte differentiation or growth plate closure timing, the drug could theoretically affect linear growth. No human data exist to confirm or refute this.

2. Bone quality vs. bone quantity. Rapidly increasing BMD in a skeleton that is still modeling may produce dense but architecturally abnormal bone. The clinical significance of this remains speculative.

3. Rebound bone loss. After romosozumab discontinuation in adults, BMD gains are lost within 12-24 months unless followed by an antiresorptive agent [8]. In an adolescent, the implications of this rebound during a period of active skeletal development are unpredictable.

Off-Label Pediatric Contexts Where Romosozumab Has Been Discussed

Despite the absence of approval, romosozumab occasionally enters clinical conversations for adolescents with rare, severe bone-fragility conditions. The most common scenario involves osteogenesis imperfecta (OI), a genetic disorder of collagen synthesis that causes bone fragility and recurrent fractures. Bisphosphonates, particularly intravenous pamidronate and zoledronic acid, have been the standard of care for moderate-to-severe pediatric OI for over two decades [9].

Some pediatric bone specialists have expressed interest in sclerostin antibody therapy for OI, given that the anabolic mechanism differs from bisphosphonates' antiresorptive action. A phase 2 trial of setrusumab, a different anti-sclerostin antibody, in adults with OI type I, III, and IV showed increases in bone formation markers and BMD at 12 months [10]. Setrusumab is not romosozumab, but the shared mechanism has led to informal clinical speculation about romosozumab as an alternative.

Other rare pediatric scenarios where romosozumab has been theoretically discussed include:

• Glucocorticoid-induced osteoporosis in adolescents on chronic prednisone for inflammatory bowel disease, systemic lupus, or organ transplant
• Cancer treatment-related bone loss in survivors of childhood leukemia or lymphoma who received prolonged corticosteroids or cranial radiation affecting the hypothalamic-pituitary axis
• Immobilization osteoporosis in adolescents with spinal cord injuries or neuromuscular diseases

In each of these scenarios, current Endocrine Society guidelines recommend bisphosphonates as first-line pharmacotherapy for pediatric patients with clinically significant bone fragility, defined as two or more long-bone fractures by age 10 or three or more by age 19, combined with low BMD (Z-score ≤ -2.0) [11]. Romosozumab does not appear in any pediatric guideline as of mid-2026.

How Adolescent Bone Differs from Adult Bone

Understanding why adult osteoporosis drug data cannot be directly extrapolated to teenagers requires a brief review of skeletal physiology. Peak bone mass, the maximum bone density a person achieves, is typically reached between ages 25 and 30. During adolescence, bone acquisition is at its most rapid phase. A longitudinal study published in the Journal of Bone and Mineral Research found that approximately 26% of total adult bone mineral content is accrued during the two years surrounding peak height velocity, roughly ages 12-14 in girls and 14-16 in boys [12].

This rapid acquisition rate means the skeleton's turnover markers look dramatically different from an osteoporotic adult's. Serum P1NP (procollagen type I N-propeptide, a bone formation marker) in healthy adolescents can be 5 to 10 times higher than in postmenopausal women [13]. CTX (C-terminal telopeptide, a resorption marker) is similarly elevated. Romosozumab's mechanism, stimulating formation and suppressing resorption, would be acting on a system already running at full metabolic capacity. The pharmacodynamic response in this context is genuinely unpredictable.

The International Society for Clinical Densitometry (ISCD) recommends using Z-scores rather than T-scores for bone density assessment in patients under 20, because comparing a 14-year-old's BMD to that of a peak-bone-mass adult produces clinically misleading results [14]. This technical point also means that the BMD outcomes reported in FRAME and ARCH, calibrated against T-score changes in postmenopausal women, cannot be directly compared to any adolescent measurement.

What Would a Romosozumab Adolescent Trial Need to Show

No registered trial of romosozumab in patients under 18 appears on ClinicalTrials.gov as of May 2026. If such a trial were designed, several endpoints and safety measures would be necessary based on FDA guidance for pediatric drug development:

Primary safety endpoints would need to include serial echocardiography and carotid intima-media thickness measurements to monitor for vascular effects. Growth velocity tracking with serial bone-age radiographs would be mandatory.

Efficacy endpoints could not rely solely on BMD. Fracture reduction, the gold standard in adult osteoporosis trials, would require very large sample sizes given the low absolute fracture rate in most adolescent populations outside of OI. Bone formation markers (P1NP) and resorption markers (CTX, TRAP-5b) would likely serve as pharmacodynamic surrogates.

Duration would need to extend beyond the standard 12-month adult treatment course to capture effects on growth plate closure and post-treatment bone remodeling. A minimum 24-month follow-up after treatment completion would be reasonable.

Dr. Laura Bachrach, former chief of pediatric endocrinology at Stanford, has written that "the bar for introducing a new bone agent in children must be higher than in adults, because the developing skeleton has repair and modeling capacities that make the risk-benefit calculus fundamentally different" [15].

Current Recommendations for Adolescent Bone Fragility

For clinicians managing adolescents with significant bone fragility, the evidence supports a stepwise approach that does not include romosozumab at this time.

First-line interventions are non-pharmacologic: optimization of calcium intake (1 to 300 mg/day for ages 9-18 per the National Institutes of Health dietary reference intakes), vitamin D repletion to a serum 25(OH)D level of at least 30 ng/mL, weight-bearing exercise, and correction of any underlying endocrine disorder (delayed puberty, hypogonadism, growth hormone deficiency, hyperthyroidism) [16].

Second-line pharmacotherapy, when fractures occur despite optimization, consists of intravenous bisphosphonates. Pamidronate (1 mg/kg IV every 3-4 months) and zoledronic acid (0.05 mg/kg IV every 6 months) have the longest track record in pediatric OI and glucocorticoid-induced osteoporosis [9]. Oral bisphosphonates are used less frequently in adolescents due to adherence concerns and lower gastrointestinal tolerability.

Emerging options under active investigation include setrusumab for OI, denosumab in selected pediatric populations (with awareness of severe rebound hypercalcemia and vertebral fractures upon discontinuation), and recombinant parathyroid hormone analogs in specific rare conditions.

Romosozumab sits outside all of these pathways for the 12-17 age group. Until a dedicated adolescent trial demonstrates both efficacy and an acceptable safety profile, the drug should be considered investigational in this population.

Monitoring Recommendations If Off-Label Use Occurs

In the rare event that a pediatric bone specialist prescribes romosozumab off-label to an adolescent (for example, a 16-year-old with severe OI unresponsive to bisphosphonates), a rigorous monitoring protocol would be necessary. No professional society has published formal guidance for this scenario, but extrapolating from adult protocols and pediatric bisphosphonate monitoring standards, a reasonable framework would include:

• Baseline and quarterly lipid panels and high-sensitivity CRP to track any emerging cardiovascular signal
• Baseline echocardiogram with repeat at 6 and 12 months
• Monthly blood pressure monitoring
• Bone turnover markers (P1NP, CTX) at baseline, 1, 3, 6, and 12 months
• DXA scans at baseline, 6, and 12 months using age-matched Z-scores per ISCD pediatric guidelines [14]
• Bone-age radiographs at baseline and 12 months to assess growth plate status
• Standing height measured monthly to detect any growth velocity changes
• Serum calcium, phosphorus, alkaline phosphatase, and 25(OH)D at regular intervals

Post-treatment, the patient would need transition to an antiresorptive (most likely a bisphosphonate) to preserve BMD gains and prevent rebound bone loss. Follow-up should extend at least 24 months beyond the last romosozumab dose.